Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Revvity (RVTY) vs. Twist Bioscience (TWST): Weighing Steady Growth Against High-Growth Potential

Revvity (RVTY) vs. Twist Bioscience (TWST): Weighing Steady Growth Against High-Growth Potential

Key Takeaways

  • RVTY is a profitable, diversified life sciences and diagnostics leader showing broad-based organic growth and consistent guidance increases.
  • TWST is a high-growth synthetic biology company delivering faster revenue expansion but still posting GAAP (Generally Accepted Accounting Principles) net losses.
  • Both stocks have outperformed the broader market in 2026, though TWST carries materially higher volatility and valuation-driven risk.
  • Tickeron AI Verdict: RVTY — the AI favors Revvity for its profitability, trend consistency, and steadier market positioning relative to Twist Bioscience.
  • Explore RVTY Major News and RVTY Today's Price Move, along with TWST Major News and TWST Today's Price Move, for more detailed coverage of each ticker.
  • For curated AI-driven trading strategies across the market, visit Trending AI Robots.

Introduction: Two Distinct Profiles in Life Sciences

Investors weighing exposure to the life sciences and genomics sectors frequently encounter two distinct profiles: RVTY (Revvity, Inc.), a diversified provider of diagnostics and research tools, and TWST (Twist Bioscience Corporation), a synthetic biology company focused on DNA synthesis. This stock comparison examines how these two companies differ in business model, profitability, momentum, and market positioning. It is most relevant for traders and investors deciding between a steady, cash-generating healthcare technology franchise and a faster-growing but unprofitable growth story tied to AI-driven drug discovery. Understanding their relative performance and risk profiles can help clarify which better fits a given portfolio objective. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

Revvity's Recent Momentum and Results

Revvity, formerly PerkinElmer, provides health sciences solutions spanning instruments, reagents, software, and diagnostic platforms used in research, newborn screening, and infectious disease testing. In recent weeks, the company reported quarterly revenue of approximately $729 million, up 10.3% year over year, with pro forma organic growth of about 7%. Management credited improving demand from pharmaceutical and biotechnology customers, broad-based diagnostics strength, and incremental demand related to artificial intelligence (AI) workflows. Revvity also raised its full-year revenue and adjusted earnings guidance, and continued advancing the divestiture of its China Immunodiagnostics business. The stock has delivered strong relative performance, with a year-to-date return well above the S&P 500, reflecting solid momentum and improving end-market conditions across its two core segments.

Twist Bioscience's Growth Trajectory

Twist Bioscience writes DNA on silicon using a proprietary semiconductor-based platform, enabling customers to synthesize millions of unique DNA sequences in parallel. Its two segments — next-generation sequencing (NGS) applications and DNA synthesis and protein solutions (DSPS) — have driven accelerating growth. In its most recent fiscal quarter, revenue rose 28% to about $126.6 million, marking a 15th consecutive quarter of sequential growth, and the company achieved its first positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) quarter. AI drug discovery revenue surged roughly 175% year over year to about $59 million for the fiscal year. However, the company remains unprofitable on a GAAP basis, and shares pulled back sharply after fiscal 2027 guidance implied a deceleration in base-business growth, underscoring the stock's sensitivity to expectations. From what I see, this highlights the execution risks that come with rapid expansion.

Head-to-Head: Business Models and Risk Profiles

The two companies differ sharply in business model and financial profile. Revvity is a diversified, profitable operator with positive adjusted earnings, strong free cash flow conversion, and a market capitalization near $17 billion. Twist Bioscience is a smaller, faster-growing company with a market capitalization under $10 billion that is still generating GAAP net losses. Growth drivers also diverge: Revvity benefits from recovering pharma and biotech demand and early AI-related instrument and reagent demand, while Twist is leveraged more directly to the expansion of AI-enabled drug discovery and personalized medicine. On momentum, both have posted impressive 2026 gains, but Twist's shares are considerably more volatile, reacting sharply to guidance nuance, while Revvity's price action has been steadier. From a risk standpoint, Twist carries greater valuation and execution risk tied to unproven profitability, whereas Revvity's principal risks include China exposure and moderating near-term growth.

AI Assessment of the Two Stocks

Based on observable factors, Tickeron's AI would likely favor RVTY over TWST in the current environment. Revvity combines established profitability, strong free cash flow, broad-based organic growth, and a track record of consistent guidance increases — characteristics associated with trend consistency and stability. Twist Bioscience offers superior top-line growth and an attractive AI drug discovery narrative, but its continued GAAP losses, higher volatility, and sensitivity to guidance expectations introduce greater uncertainty. While both stocks hold valid long-term investment theses, the balance of stability, catalysts, and relative positioning currently tilts the AI's assessment toward Revvity.

Using AI Tools for Deeper Analysis

In my analysis of these names, I turned to Tickeron’s AI Trend Prediction Engine to evaluate forward momentum and compare trend signals across the sector. This helped confirm the steadier profile for one name over the other based on historical patterns and current data inputs. It offers a practical way to layer quantitative insights onto fundamental research without replacing individual judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RVTY, TWST

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RVTY in downward trend: price may drop because broke its higher Bollinger Band on October 23, 2026

RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 31 of the 39 cases the stock fell afterwards. This puts the odds of success at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RVTY moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 17 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.

The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 34 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

RVTY moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on RVTY as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

The Aroon Indicator entered an Uptrend today. In 117 of 189 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.394) is normal, around the industry mean (67.298). P/E Ratio (74.572) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -7%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was 19%. VCYT experienced the highest price growth at 2%, while ADVB experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was -46% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 48
SMR Rating: 78
Profit Risk Rating: 87
Seasonality Score: 25 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of analytical instruments

Industry MedicalSpecialties

Industry
Medical Specialties
Address
77 4th Avenue
Phone
+1 781 663-6900
Employees
11000
Web
https://www.revvity.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.